Can Nutraceuticals Prevent Alzheimer's Disease? Potential Therapeutic Role of a Formulation Containing Shilajit and Complex B Vitamins

Archives of Medical Research

Volumn 43, Issue 8, 2012, Pages 699-704

  Carrasco Gallardo, Carlos ^a,b   Farías, Gonzalo A ^a   Fuentes, Patricio ^c   Crespo, Fernando ^d   Maccioni, Ricardo B ^a,b  

^a ICC   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^d UNIVERSIDAD DE VALPARAÍSO   (Chile)

Author keywords

Alzheimer's disease; Fulvic acid; Functional foods; Nutraceuticals; Shilajit; Tau protein

Indexed keywords

FULVIC ACID; NUTRACEUTICAL; SHILAJEET; VITAMIN B COMPLEX;

ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; MEDICAL LITERATURE; REVIEW;

ALZHEIMER DISEASE; BENZOPYRANS; BRAIN; CONTROLLED CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; FUNCTIONAL FOOD; HUMANS; HUMIC SUBSTANCES; MEDICINE, AYURVEDIC; RESINS, PLANT; VITAMIN B COMPLEX;

EID: 84871643520     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.10.010     Document Type: Review

References (56)

1. Wimo A., Prince M. World Alzheimer Report 2010: The global economic impact of dementia. Alzheimer's Dis Int 2010, 1:39-42.
2. Sambamurti K., Greig N., Utsuki T., et al. Targets for Alzheimer's disease treatment: conflicting messages from γ secretase inhibitors. J Neurochem 2011, 3:359-374.
3. Saxena U. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?. Expert Opin Ther Targets 2010, 14:1273-1277.
4. Hardy J., Selkoe D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
5. Maccioni R., Rojo L., Farías G., et al. In search of therapeutic solutions for Alzheimer's disease. When Things Go Wrong: Brain Disorders 2012, 125-150. InTech Editions, London.
6. Piau A., Nourhashémi F., Hein C., et al. Progress in the development of new drugs in Alzheimer's disease. J Nutr Health Aging 2011, 15:45-57.
7. Ji H., Zhang H. Multipotent natural agents to combat Alzheimer's disease. Functional spectrum and structural features. Acta Pharmacol Sin 2008, 29:143-151.
8. Maccioni R.B., Muñoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001, 32:367-381.
9. Mandelkow E., Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. The Biology of Alzheimer Disease 2012, 133-157. Cold Spring Harbor Persp. Med. D. Selkoe, E. Mandelkow, D. Holtzman (Eds.).
10. Billingsley M., Kincaid R. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodeeneration. Biochem J 2007, 323:577-591.
11. Maccioni R.B., Farías G., Morales I., et al. The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 2010, 41:226-231.
12. Farías G., Pérez P., Slachevsky A., et al. Platelet tau pattern correlates with cognitive status in Alzheimer's disease. J Alzheimers Dis 2012, 31:65-69.
13. Neumann K., Farías G., Slachevsky A., et al. Human platelets tau: a potential peripheral marker for Alzheimer's disease. J Alzheimers Dis 2011, 25:103-109.
14. Navarrete L., Guzmán L., San Martín A., et al. Molecules of the quinoline family block tau self-aggregation: implications toward a therapeutic approach for Alzheimer's disease. J Alzheimers Dis 2012, 29:79-88.
15. Cornejo A., Jiménez J.M., Caballero L., et al. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease. J Alzheimers Dis 2011, 27:143-153.
16. de Silva A., Lanerolle P. Nutraceuticals: concepts and controversies. Ceylon Med J 2011, 56:171-173.
17. Penumetcha M., Santanam N. Nutraceuticals as ligands of PPARγ. PPAR Res 2012, 2012:1-7.
18. Jacobs D., Gross M., Tapsell L. Food sunergy: an operational concept for undestanding nutrition. Am J Clin Nutr 2009, 89(suppl):1543-1548.
19. Arai S. Studies on functional foods in Japan-state of the art. Biosci Biotechnol Biochem 1996, 60:9-15.
20. Zeisel S. Regulation of nutraceuticals. Science 1999, 285:1853-1855.
21. BCC Report. Nutraceuticals: Global Markets and Processing Technologies. BCC Report, FOD013D, 2011.
22. Pivi G., da Silva R., Juliano Y., et al. A prospective study of nutrition education and oral nutritional supplementation in patients with Alzheimer's disease. Nutr J 2011, 10:98.
23. Gu Y., Nieves J., Stern Y., et al. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 2010, 67:699-706.
24. Ansari N., Houlihan L., Hussain B., et al. Antioxidant activity of five vegetables traditionally consumed by south-Asian migrants in Bradford, Yorkshire, UK. Phytother Res 2005, 19:907-911.
25. Refsum H., Smith A.D., Ueland P., et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004, 50:3-32.
26. Smith A. Homocysteine, B vitamins, and cognitive deficit in the elderly (editorial). Am J Clin Nutr 2002, 75:785-786.
27. Smith A, Smith S, de Jager C, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS ONE 5:e12244. doi:. doi:10.1371/journal.pone.0012244.
28. Klee G. Cobalamin and folate evaluation;measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. Clin Chem 2000, 46:1277-1283.
29. Langan R., Zawistoski K. Update on vitamin B12 deficiency. Am Fam Physician 2011, 83:1425-1430.
30. Carrasco-Gallardo C., Guzmán L., Maccioni R.B. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzeimers Dis 2012, 2012:1-4.
31. Ghosal S. Chemistry of Shilajit, an immunomodulatory Ayurvedic rasayan. Pure Appl Chem (IUPAC) 1990, 62. 1285-128.
32. Agarwal S.P., Khanna R., Karmarkar R., et al. Shilajit: a Review. Phytother Res 2007, 21:401-405.
33. Oxford A., Raistrick H., Simonart P. Studies in the biochemistry of micro-organisms: fulvic acid, a new crystalline yellow pigment, a metabolic product of P. griseo-fulvum Dierckx, P. flexuosum Dale and P. brefeldianum Dodge. Biochem J 1935, 5:1102-1115.
34. Islam K., Schumacher A., Gropp J. Humic acid substances in animal agriculture. Pak J Nutr 2005, 4:126-134.
35. Zang X., van Heemst J., Dria K., et al. Encapsulation of protein in humic acid from a histosol as an explanation for the occurrence of organic nitrogen in soil and sediment. Org Geochem 2000, 31:679-695.
36. Sutton R., Sposito G. Molecular structure in soil humic substances: the new view. Environ Sci Technol 2005, 39:9009-9015.
37. Tan W., Koopal L., Weng L., et al. Humic acid protein complexation. Geochim Cosmochim Acta 2008, 72:2090-2099.
38. Tomaszewski J., Schwarzenbach R., Sander M. Protein encapsulation by humic substances. Environ Sci Technol 2011, 45:6003-6010.
39. Sergeant N., Bretteville A., Hamdane M., et al. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 2008, 5:207-224.
40. Ghosal S., Singh S.K., Kumar Y., et al. Antiulcerogenic properties of fulvic acids and 4-methoxy-6-carbomethoxybiphenyl isolated from shilajit. Phytother Res 1988, 2:187-191.
41. Bhattacharya S., Sen A. Effects of shilajit on biogenic free radicals. Phytother Res 1995, 9:56-59.
42. Ghosal S., Lata S., Gaur K.Y.B., et al. Interaction of shilajit with biogenic free radicals. Indian J Chem B 1995, 34:596-602.
43. Schepetkin I., Xie G., Jutila M., et al. Complement-fixing activity of fulvic acid from shilajit and other natural sources. Phytother Res 2009, 23:373-384.
44. Ghosal S., Lal J., Singh S., et al. The need for formulation of shilajit by its isolated active constituents. Phytother Res 1991, 5:211-216.
45. Acharya S., Frotan M., Goel R., et al. Pharmacological actions of shilajit. Indian J Exp Biol 1988, 26:775-777.
46. Shalini S. Antifungal activity screening and hplc analysis of crude extract from Tectona grandis, shilajit, Valeriana wallachi. Elec J Env Agricult Food Chem 2009, 8:218-229.
47. Mirza M., Agarwal S., Rahman M., et al. Role of humic acid on oral drug delivery of an antiepileptic drug. Drug Dev Ind Pharm 2011, 37:310-319.
48. Meena H., Pandey H., Arya M., et al. Shilajit: a panacea for high-altitude problems. Int J Ayurveda Res 2010, 1:37-40.
49. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
50. Folstein M., Folstein S., McHugh P. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
51. Mohs R., Knopman D., Petersen R., et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997, 2(suppl):13-21.
52. Kaufer D., Cummings J., Christine D., et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998, 46:210-215.
53. Reisberg B., Ferris S., de Leon M., et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982, 139:1136-1139.
54. Saper R., Phillips R., Sehgal A., et al. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the internet. J Am Med Assoc 2008, 300:915-923.
55. Espín J., García-Conesa M.T., Tomás-Barberán F.A. Nutraceuticals: facts and fiction. Phytochem 2007, 68:2986-3008.
56. Davi G., Santilli F., Patrono G. Nutraceuticals in diabetes and metabolic syndrome. Cardiovasc Ther 2010, 28:216-226.